Denmark· DK-28104131807
Granisetron "Hameln"
A granisetron product containing granisetronhydrochlorid, registered in Denmark by hameln pharma GmbH. The same ATC class is registered in 18 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Granisetron is registered in 18 of 19 countries.
Countries holding a registration under ATC A04AA02 (granisetron), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 10 of them publish a price we can compare per daily dose
Granisetron · ATC A04AA02
18 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of granisetron costs, country by country.
Normalised to the WHO defined daily dose (2 mg), the median price runs from $10.02 in Italy to $29.01 in Switzerland — a ×2.9 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Granisetron · price per daily dose (2 mg)
USD · FX 28 Sept 2026
- CH Switzerland$29.01
- FR France$11.60
- IT Italy$10.02
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- GRANISETRONHYDROCHLORID
- Manufacturer
- hameln pharma GmbH
- Country
- Denmark (DK)
- ATC code
- A04AA02
- ATC class
- Granisetron
- Defined daily dose
- 2 mg, O
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28104131807
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
564 interactions on record for granisetron.
Graded by severity as the source publishes them — 139 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Granisetron · interactions on record
564 records
- 139 severe
- 244 moderate
- 9 minor
- 172 info
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- FenfluramineA08AA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under A04AA02
Granisetron, as other registers publish it.
- CanadaAPO-GRANISETRONAPOTEX INC
- FinlandGazoronSTADA Arzneimittel AG
- FinlandGazoronSTADA Arzneimittel AG
- ItalyGRANDISELANOVA FARMACEUTICI S.R.L.
- ItalyGRANDISELANOVA FARMACEUTICI S.R.L.
- CzechiaGRANEGISEgis Pharmaceuticals PLC, Budapešť
- CzechiaGRANEGISEgis Pharmaceuticals PLC, Budapešť
- CzechiaGRANEGISEgis Pharmaceuticals PLC, Budapešť
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/aaddbf38-441e-41c8-aede-15fee98c73d2 GET /v1/drugs/aaddbf38-441e-41c8-aede-15fee98c73d2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "koncentrat til injektions-/infusionsvæske, opløsning",
"source": "dkma",
"strength": "1 mg/ml",
"auth_role": "CMS",
"dk_drugid": "28104131807",
"substance": "GRANISETRONHYDROCHLORID",
"auth_procedure": "Decentral procedure",
"in_medicinpriser": false,
"registration_date_serial": "39675"
}See everything about granisetron.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.